Please login to the form below

Not currently logged in
Email:
Password:

Mersana appoints Anna Protopapas as president and CEO

Joins from Millenium Pharmaceuticals

Anna ProtopapasMersana Therapeutics has named Anna Protopapas as president and CEO.

Protopapas joins the firm, which engineers antibody-drug conjugates (ADCs), from Takeda subsidiary Millennium Pharmaceuticals, where she held the same role.

Commenting on her new role, Protopapas said: “ADCs are a proven approach to cancer with two drugs on the market and over 30 in the clinic. Mersana's Fleximer-ADCs are a best-in-class approach, which overcomes the limitations of other ADC technologies.

“I am very encouraged by the results to date and look forward to working alongside the team at Mersana to translate the technology into important therapies for patients.”

Protopapas has expansive strategic leadership experience, with a demonstrated track record in the biopharma industry. Amongst her time in the sector, Protopapas has served as a member of the executive committee of Takeda, led Takeda's oncology business during her time at Millennium Pharmaceuticals and also held the role of executive VP of global business development.

Protopapas will additionally join Mersana's board of directors.

4th March 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics